|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pastorino U: Lung cancer screening. Br J
Cancer. 102:1681–1686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gettinger S and Lynch T: A decade of
advances in treatment for advanced non-small cell lung cancer. Clin
Chest Med. 32:839–851. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Javle M, Pande A, Iyer R, Yang G, LeVea C,
Wilding G, Black J, Nava H and Nwogu C: Pilot study of gefitinib,
oxaliplatin, and radiotherapy for esophageal adenocarcinoma: Tissue
effect predicts clinical response. Am J Clin Oncol. 31:329–334.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masago K, Fujita S, Irisa K, Kim YH,
Ichikawa M, Mio T and Mishima M: Good clinical response to
gefitinib in a non-small cell lung cancer patient harboring a rare
somatic epidermal growth factor gene point mutation; codon 768 AGC
> ATC in exon 20 (S768I). Jpn J Clin Oncol. 40:1105–1109. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferry DR, Anderson M, Beddard K, Tomlinson
S, Atherfold P, Obszynska J, Harrison R and Jankowski J: A phase II
study of gefitinib monotherapy in advanced esophageal
adenocarcinoma: Evidence of gene expression, cellular, and clinical
response. Clin Cancer Res. 13:5869–5875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jackman DM, Holmes AJ, Lindeman N, Wen PY,
Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA and Johnson BE:
Response and resistance in a non-small-cell lung cancer patient
with an epidermal growth factor receptor mutation and
leptomeningeal metastases treated with high-dose gefitinib. J Clin
Oncol. 24:4517–4520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang S, Qin C, Cao G, Xin W, Feng C and
Zhang W: Systematic analysis of long noncoding RNAs in the
senescence-accelerated mouse prone 8 brain using RNA sequencing.
Mol Ther Nucleic Acids. 5:e3432016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keniry A, Oxley D, Monnier P, Kyba M,
Dandolo L, Smits G and Reik W: The H19 lincRNA is a developmental
reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell
Biol. 14:659–665. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding D, Li C, Zhao T, Li D, Yang L and
Zhang B: LncRNA H19/miR-29b-3p/PGRN axis promoted
epithelial-mesenchymal transition of colorectal cancer cells by
acting on Wnt signaling. Mol Cells. 41:423–435. 2018.PubMed/NCBI
|
|
12
|
Conigliaro A, Costa V, Lo Dico A, Saieva
L, Buccheri S, Dieli F, Manno M, Raccosta S, Mancone C, Tripodi M,
et al: CD90+ liver cancer cells modulate endothelial cell phenotype
through the release of exosomes containing H19 lncRNA. Mol Cancer.
14:1552015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li
TL, Cai JQ, Zhou HH and Zhu YS: H19 lncRNA mediates
17β-estradiol-induced cell proliferation in MCF-7 breast cancer
cells. Oncol Rep. 33:3045–3052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Théry C, Ostrowski M and Segura E:
Membrane vesicles as conveyors of immune responses. Nat Rev
Immunol. 9:581–593. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pefanis E, Wang J, Rothschild G, Lim J,
Kazadi D, Sun J, Federation A, Chao J, Elliott O, Liu ZP, et al:
RNA exosome-regulated long non-coding RNA transcription controls
super-enhancer activity. Cell. 161:774–789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fustaino V, Presutti D, Colombo T,
Cardinali B, Papoff G, Brandi R, Bertolazzi P, Felici G and Ruberti
G: Characterization of epithelial-mesenchymal transition
intermediate/hybrid phenotypes associated to resistance to EGFR
inhibitors in non-small cell lung cancer cell lines. Oncotarget.
8:103340–103363. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Presutti D, Santini S, Cardinali B, Papoff
G, Lalli C, Samperna S, Fustaino V, Giannini G and Ruberti G: MET
gene amplification and met receptor activation are not sufficient
to predict efficacy of combined MET and EGFR inhibitors in EGFR
TKI-resistant NSCLC cells. PLoS One. 10:e01433332015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu SY, Huang X and Cheong KL: Recent
advances in marine algae polysaccharides: Isolation, structure, and
activities. Mar Drugs. 15:pii: E3882017. View Article : Google Scholar
|
|
19
|
Villarroya-Beltri C, Gutiérrez-Vázquez C,
Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martin-Cofreces N,
Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M and
Sánchez-Madrid F: Sumoylated hnRNPA2B1 controls the sorting of
miRNAs into exosomes through binding to specific motifs. Nat
Commun. 4:29802013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xin H, Li Y, Buller B, Katakowski M, Zhang
Y, Wang X, Shang X, Zhang ZG and Chopp M: Exosome-mediated transfer
of miR-133b from multipotent mesenchymal stromal cells to neural
cells contributes to neurite outgrowth. Stem Cells. 30:1556–1564.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valencia K, Luis-Ravelo D, Bovy N, Antón
I, Martínez-Canarias S, Zandueta C, Ormazábal C, Struman I, Tabruyn
S, Rebmann V, et al: miRNA cargo within exosome-like vesicle
transfer influences metastatic bone colonization. Mol Oncol.
8:689–703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang Y, Soroush F, Tong Z, Kiani MF and
Wang B: Targeted multidrug delivery system to overcome
chemoresistance in breast cancer. Int J Nanomedicine. 12:671–681.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Melosky B: Review of EGFR TKIs in
metastatic NSCLC, including ongoing trials. Front Oncol. 4:2442014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dhillon S: Gefitinib: A review of its use
in adults with advanced non-small cell lung cancer. Target Oncol.
10:153–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kani K, Garri C, Tiemann K, Malihi PD,
Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, et al:
JUN-mediated downregulation of EGFR signaling is associated with
resistance to gefitinib in EGFR-mutant nsclc cell lines. Mol Cancer
Ther. 16:1645–1657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Z, Lei W, Hu HB, Zhang H and Zhu Y:
H19 promotes non-small-cell lung cancer (NSCLC) development through
STAT3 signaling via sponging miR-17. J Cell Physiol. 233:6768–6776.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Denzer K, Kleijmeer MJ, Heijnen HF,
Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the
multivesicular body to intercellular signaling device. J Cell Sci.
113:3365–3374. 2000.PubMed/NCBI
|
|
29
|
Kucharzewska P and Belting M: Emerging
roles of extracellular vesicles in the adaptive response of tumour
cells to microenvironmental stress. J Extracell Vesicles. 2:2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kourembanas S: Exosomes: Vehicles of
intercellular signaling, biomarkers, and vectors of cell therapy.
Annu Rev Physiol. 77:13–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Liu R, Huang Z, Gurley EC, Wang X,
Wang J, He H, Yang H, Lai G, Zhang L, et al: Cholangiocyte-derived
exosomal long noncoding RNA H19 promotes cholestatic liver injury
in mouse and humans. Hepatology. 68:599–615. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pigati L, Yaddanapudi SC, Iyengar R, Kim
DJ, Hearn SA, Danforth D, Hastings ML and Duelli DM: Selective
release of microRNA species from normal and malignant mammary
epithelial cells. PLoS One. 5:e135152010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alarcón CR, Goodarzi H, Lee H, Liu X,
Tavazoie S and Tavazoie SF: HNRNPA2B1 is a mediator of
m(6)A-dependent nuclear RNA processing events. Cell. 162:1299–1308.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang J, Qin G, Luo M, Chen J, Zhang Q, Li
L, Pan L and Qin S: Reciprocal positive regulation between Cx26 and
PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC
cells via GJIC-independent induction of EMT. Cell Death Dis.
6:e18292015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jeannot V, Busser B, Brambilla E, Wislez
M, Robin B, Cadranel J, Coll JL and Hurbin A: The PI3K/AKT pathway
promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by
a deacetylase-dependent mechanism. Int J Cancer. 134:2560–2571.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chiu CF, Chang YW, Kuo KT, Shen YS, Liu
CY, Yu YH, Cheng CC, Lee KY, Chen FC, Hsu MK, et al: NF-κB-driven
suppression of FOXO3a contributes to EGFR mutation-independent
gefitinib resistance. Proc Natl Acad Sci USA. 113:E2526–E2535.
2016. View Article : Google Scholar : PubMed/NCBI
|
